
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS has demonstrated a significant enhancement in the prediction accuracy of its PIONEER AI model, now achieving 81% immunogenicity for predicted neoantigens, thus reinforcing its leadership in neoantigen cancer vaccine development. The impressive overall response rate (ORR) of 75% for patients treated with the combination of EVX-01 and pembrolizumab, coupled with a favorable safety profile, positions the company favorably compared to competitors, such as Moderna. Additionally, the data reveals not only sustained responses in patients undergoing treatment but also deepened responses, contributing to a robust outlook for Evaxion’s innovative immunotherapy pipeline targeting critical unmet medical needs in oncology and infectious diseases.
Bears say
Evaxion AS's stock has shown a negative reaction despite a strong data update on its EVX-01 product, indicating a disconnect between the company's advancements and investor expectations. The lack of a clear indication of EVX-01’s contribution may have heightened investor skepticism regarding the company's ability to deliver on its promises within its oncology pipeline. This situation raises concerns about market confidence in Evaxion's financial sustainability and the execution of its innovative strategies.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares